Case report: Apatinib combined with neoadjuvant therapy for primary squamous cell carcinoma of the breast: a case report

Fangfang Gao; Jingtai Li; Haoran Liao; Pingming Fan; Minjian Wang; Yu Liu; Linwei Ding; Guankui Du

doi:10.3389/fphar.2023.1115422

Case report: Apatinib combined with neoadjuvant therapy for primary squamous cell carcinoma of the breast: a case report

Front Pharmacol. 2023 May 11:14:1115422. doi: 10.3389/fphar.2023.1115422. eCollection 2023.

Authors

Fangfang Gao¹, Jingtai Li¹, Haoran Liao¹, Pingming Fan^{1

2}, Minjian Wang³, Yu Liu¹, Linwei Ding⁴, Guankui Du^{1

4

5

6}

Affiliations

¹ Department of Breast Surgery, The First Affiliated Hospital of Hainan Medical University, Haikou, China.
² Guangxi Medical University Cancer Hospital, Nanning, China.
³ Department of Pathology, The First Affiliated Hospital of Hainan Medical University, Haikou, China.
⁴ Key Laboratory of Molecular Biology, Hainan Medical University, Haikou, China.
⁵ Department of Biochemistry and Molecular Biology, Hainan Medical University, Haikou, China.
⁶ Biotechnology and Biochemistry Laboratory, Hainan Medical University, Haikou, China.

Abstract

Primary squamous cell carcinoma of the breast is a rare subtype of carcinoma of chemosis for which there is no effective chemotherapy regimen. Breast squamous cell carcinoma is usually "triple negative", with poor chemotherapy effects and poor prognosis. Here, we report a successful case of primary breast squamous cell carcinoma treated with apatinib. The patient was treated with 2 cycles of apatinib. The efficacy was evaluated as partial remission, and a sublesion of approximately 4 cm fell off.

Keywords: VEGFR; apatinib; neoadjuvant; primary squamous cell carcinoma of the breast; targeted therapy.

Publication types

Case Reports